

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**INFORMATION DISCLOSURE STATEMENT**

**TRANSMITTAL FORM**

In re Application of: O'Lenick

Serial No:

Filed:

Ref: SIL-010

Commissioner of Patents and Trademarks  
Washington, D.C. 20231


Dear Sir;

Please find enclosed the following components of an information disclosure statement:

1. PTO list of patents cited
2. Discussion under rule 98
3. Cited patents as follows; 5,210,133

Applicant respectfully contends that this package conforms to the provisions of 37 C.F.R. 1.98 and 37 C.F.R. 1.97. Applicant respectfully requests that the information contained herein be considered by the examiner in charge of the case.

Respectfully submitted;

  
Anthony J. O'Lenick, Jr.  
Applicant  
February 8, 2004  
(678) 442-0210

Please type a plus sign (+) inside this box → 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	
Sheet	1	of	1	Filing Date	
				First Named Inventor	O'LEMICK
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	SIL010

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


### **Discussion Under Rule 98**

U.S. Pat. No. 5,210,133 to O'Lenick Jr, issued May 1993 discloses "novel series of silicone polyesters which are useful as delivery systems for a variety of hydroxyl containing active such as lanolin, cholesterol, dihydrocholesterol, Vitamin A, Vitamin D-2, Vitamin D-3, Vitamin D-4, Vitamin E, and panthenol. Compounds of the invention by are prepared by the esterification of (a) a hydroxyl containing silicone compound selected from silanol and dimethicone copolyol (b) a diacid and (c) a hydroxyl functional active selected from lanolin, cholesterol, dihydrocholesterol, Vitamin A, Vitamin D-2, Vitamin D-3, Vitamin D-4, Vitamin E, and panthenol; and optionally (d) a mono functional fatty acid. The polyesters of the present invention allow for the formulation of personal care products in which the "active" can be formulated into a variety of solvents without the loss of activity." These compounds are prepared by reacting hydroxyl silicones with hydroxyl containing vitamins, in the presence of diacids. A major problem with these products is based upon the fact that there is little group selectivity in the two types of hydroxyl groups reacted. This results in undesired homopolymers. Simply, there is a high concentration of vitamin cross-linked to another vitamin unit through a diacid linkage, and silicone cross-linked to silicone through a diacid group.

These undesirable by-products alter the properties of the compound. The cross-linked silicone molecule can cause gellation of the product. The vitamin cross-linked to another vitamin lacks water solubility and therefore results in products, which split into two phases. These problems have resulted in lack of commercial success of the products.

It was not until the current invention was it understood that the reaction of a silicone methyl ester with the hydroxyl vitamin that clear homogeneous cosmetically acceptable products could produced that do not split into two phases.

Respectfully submitted;



Anthony J. O'Lenick, Jr.  
Applicant  
2170 Luke Edwards Road  
Dacula, Ga 30019  
February 8, 2004  
(678) 442-0210